Emerging evidence indicates that one central common denominator of resistance to immune checkpoint inhibitors may be fibrotic activity characterized by collagen production by cancer-associated fibroblasts (CAFs).
Consequent to increased fibroblast activity, specific collagen fragments are released into the circulation and can be used as non-invasive biomarkers assessed in a liquid biopsy such as serum or plasma. PRO-C3 quantifies the formation of type III collagen and can therefore be used as a non-invasive biomarker of tumor fibrosis.
Watch more videos about Nordic Bioscience's biomarkers and technology on our YouTube channel!
How can we help you?
Please don't hesitate to contact us if you have any questions or other inquiries.
